Alexion Eculizumab Will Have "Ultra-Orphan" Price; Antibody Enters Phase III
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Alexion plans to price its biologic eculizumab for treatment of paroxysmal nocturnal hemoglobinuria similarly to other high-priced agents for very rare diseases, the firm indicated.